The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there are laboratories at Stanford working on ketamine, psilocybin, MDMA, mostly in animal models. There's terrific work going on at Johns Hopkins University School of Medicine, Matthew Johnson's Lab, and others looking at the clinical applications, mainly of high dose psilocybin and LSD. There's the maps trials with MDMA.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.